Leveraging Community Tumor Boards for Oncology Trial Dissemination: The ACOSOG Z1071 Trial
A gap remains between oncology trial data publication and incorporation of findings into practice. The goal of this video project is to utilize the multidisciplinary tumor board setting to improve knowledge of clinical trial data and increase integration of clinical trial findings into practice.
This 10-minute video reviews trial design and results from the American College of Surgeons Oncology Group (ACOSOG) Z1071 Trial, which evaluated the accuracy of sentinel lymph node biopsy after neoadjuvant chemotherapy in clinically node positive breast cancer patients. The associated discussion guide helps communities discuss the trial and formulate a plan for implementation into their clinical practice. The project was designed so the video can be watched at the multidisciplinary tumor board. The discussion guide can be used in the same setting or at a later stage.
- Surgical oncologists
- Medical oncologists
- Radiation oncologists
- Cancer conference coordinators
- Cancer program administrators
This course will:
- Give an overview of the Z1071 trial, including design, inclusion/exclusion criteria, and results.
- Provide resources to facilitate discussion of the implementation of the Z1071 trial and other clinical trials at the local level in a structured way.
- Describe the multidisciplinary impacts of the Z1071 trial.
In accordance with the ACCME Accreditation Criteria, the American College of Surgeons must ensure that anyone in a position to control the content of the educational activity (planners and speakers/authors/discussants/moderators) has disclosed all relevant financial relationships with any commercial interest (see below for definitions).
The ACCME defines a “commercial interest” as any entity producing, marketing, re-selling, or distributing health care goods or services used on or consumed by patients. Providers of clinical services directly to patients are NOT included in this definition.
Relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.
Conflict of Interest
Circumstances create a conflict of interest when an individual has an opportunity to affect CME content about products or services of a commercial interest with which he/she has a financial relationship.
The ACCME also requires that ACS manage any reported conflict and eliminate the potential for bias during the educational activity. Any conflicts noted below have been managed to our satisfaction. The disclosure information is intended to identify any commercial relationships and allow learners to form their own judgments. However, if you perceive a bias during the educational activity, please report it on the evaluation.
Faculty and Disclosures
Kelly Hunt, MD, FACS – Nothing to disclose
Chair, Department of Breast Surgical Oncology
University of Texas MD Anderson Cancer Center
Bruce Haffty, MD – Nothing to disclose
Chair, Department of Radiation Oncology
Rutgers University Cancer Institute
Program Committee and Disclosures
Abigail Caudle, MD – Nothing to disclose
Sarah Blair, MD – Nothing to disclose
Diana Dickson-Witmer, MD – Nothing to disclose
Lisa Lowenstein, PhD – Nothing to disclose
A Certificate of Completion will be awarded for this course.
This activity is not eligible for CME or CE credits.
- 1.00 Certificate of Completion